Cardiol Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Cardiol Therapeutics Stock-Based Compensation Growth & History (CRDL)
Cardiol Therapeutics's stock-based compensation was $10.7M for fiscal 2025.
View full Cardiol Therapeutics company overviewCardiol Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.7M | −$3.6M | −25.05% |
| 2024 | 2024-12-31 | $14.3M | $10.1M | +243.47% |
| 2023 | 2023-12-31 | $4.2M | −$856,423 | −17.08% |
| 2022 | 2022-12-31 | $5.0M | −$3.5M | −41.01% |
| 2021 | 2021-12-31 | $8.5M | $5.7M | +207.33% |
| 2020 | 2020-12-31 | $2.8M | — | — |
Cardiol Therapeutics quarterly stock-based compensation
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.4M | −$164,235 | −6.47% |
| Q1 2026 | 2026-03-31 | $1.8M | $695,861 | +60.67% |
| Q4 2025 | 2025-12-31 | $3.0M | — | — |
| Q3 2025 | 2025-09-30 | $4.0M | — | — |
| Q2 2025 | 2025-06-30 | $2.5M | — | — |
| Q1 2025 | 2025-03-31 | $1.1M | — | — |
Cardiol Therapeutics stock-based compensation trends
Over the last five fiscal years, Cardiol Therapeutics's stock-based compensation increased from $2.8M to $10.7M, a change of $7.9M. The latest reported quarter, Q2 2026, shows $2.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiol Therapeutics source filings ↗